Royalty Report: Cannabis, Drugs, Therapeutic – Collection: 239294

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Cannabis
  • Drugs
  • Therapeutic
  • Tobacco
  • Agriculture
  • Forestry and Fishing
  • Agriculture Forestry & Fishing
  • Crop Production
  • Cancer
  • Disease
  • Pain
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 239294

License Grant
In this agreement the Licensee is to produce cannabis-infused baked goods and other edibles in Licensor’s production facility upon approval of Licensor’s Nevada Medical Marijuana Production License.
License Property
The Company (Licensor) seeks to be an innovative technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a variety of ailments. The Company is developing and utilizing state of the art technologies in plant biology, cultivation and extraction techniques, combined with biotechnology, and plans to produce consistent and measurable medical-grade cannabis, cannabis concentrates and cannabinoid therapies.
Field of Use
This agreement pertains to the drug industry relating to cannabis-based therapeutic products.

IPSCIO Record ID: 249613

License Grant
The Canadian Licensor and Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cannabis.

IPSCIO Record ID: 365304

License Grant
Various Licensees operate a state-of-the-art cannabis cultivation, processing and manufacturing facility from the Licensor.
License Property
The facility is used for development, traditional horticulture, lean manufacturing, medical research, facility construction, regulatory compliance, security, marijuana cultivation and genetics, extraction processes, and infused product development.
Field of Use
Field of use is for medical cannabis and the newly emerging adult-use cannabis marketplace.

IPSCIO Record ID: 264659

License Grant
Licensee, a shareholder,  has a non-exclusive right to sell Prana Hemp in certain situations where the sale is to be completed through the use of a credit card associated with a merchant account owned and/or controlled by Licensee.
License Property
The intellectual property we licensed includes know-how relating to the design and buildout of cultivation facilities, growing/cultivation systems, seed-to-sale protocols and procedures, products, access to a genetic catalogue including over 150 different strains, an advanced (non-psychoactive) cannabinoid sequencing therapy program utilizing patent-pending Prana Bio Nutrient Medicinals called the A.C.T. Now Program (“ACT Now” or “ACT Now Program”), security, regulatory compliance, and other methods and processes which relate to the cannabis industry.

Licensor is a biotech company focused on developing targeted therapeutics for the prevention of the negative side effects of chemotherapy, management of rheumatoid arthritis and treatment of brain cancer. The focus is on extracting products from industrial hemp plants, which the Licensor wholesale to manufacturers, and which are used to create unique therapeutics for a wide range of diseases that can be utilized by patients globally. Licensor own distinct intellectual property relating to the legalized growth, production, manufacture, marketing, management, utilization and distribution of medical and recreational marijuana and marijuana infused products.

Field of Use
This agreement pertains to the drug industry.  The intellectual property is licensed to businesses in the cannabis industry.

IPSCIO Record ID: 345624

License Grant
Licensor hereby engages Licensee, on a non-exclusive basis, and Licensee hereby accepts such engagement and agrees, upon the terms and conditions set forth herein, to provide the Cultivation Services pursuant to the terms and conditions set forth herein. Licensee hereby is granted the right to develop, manage, and produce on behalf of Licensor all Licensee-branded products, including but not limited to those set forth; provided, however, that (a) Licensee is authorized by Licensor to produce all products that may be lawfully grown and distributed in Nevada pursuant to applicable law, including CCB guidelines and the RTMA; (b) Licensee shall use commercially-reasonable efforts to maximize the production and sales of the products grown at the Cultivation Facility under this Agreement, subject to compliance with all applicable laws; (c) Licensee shall commence making its improvements to the Designated Acreage within 120 calendar days of the date of the Commencement Notice and shall begin cultivation on the Designated Acreage (as evidenced by registration of the first plants with the CCB) by the first day of Spring following the Commencement Notice or when the CCB approves cultivation activities at the Designated Acreage, whichever occurs later; and (d) Licensee complies with all applicable laws, rules, and regulations, including but not limited to those pertaining to the labeling of product sold hereunder.
License Property
Product shall include but not limited to Cannabis / Marijuana on the Designated Acreage and selling in the State of Nevada.
Field of Use
Field of use is for a cultivation facility license to cultivate (grow), process, and package marijuana; sell marijuana to retail marijuana stores; and operate marijuana product manufacturing facilities and sell to other cultivation facilities.

IPSCIO Record ID: 249612

License Grant
The Canadian Licensor and Canadian Licensee have agreed to collaborate to develop and manufacture a line of at least 3 co-branded topical cosmetic products formulated with a cannabinoid or cannabinoids.
License Property
Cannabis is a plant used in products for medical proposes.
Field of Use
This agreement pertains to the drug industry relating to cosmetic products.

IPSCIO Record ID: 265496

License Grant
The Canadian Company obtained an exclusive licence to exploit exclusive varieties of cannabis and access to extensive data that Licensor had gathered from thousands of its patients for over a decade.
License Property
Licensor is a research and development-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis.
Field of Use
This agreement pertains to the drug industry relating to the cannabis market.

IPSCIO Record ID: 254191

License Grant
The Licensee entered into an exclusive worldwide license to sublicense, use, develop, promote, sell or otherwise commercialize in any way a technology to produce and distribute cannabis products with exceedingly precise dosing at increased production economies.
License Property
The cannabis-infused products are to treat specific medical conditions.
Field of Use
This agreement pertains to the drug industry relating to the cannabis industry.

IPSCIO Record ID: 257250

License Grant
The Israeli Licensor and the Cayman Islands Licensee hereby agree to the amendment of the License Agreement (the 'First Amendment') to amend the product definition and the royalty consideration for Over the Counter Pharmaceutical Products.
License Property
Pharmaceutical Product shall mean, with respect to each jurisdiction in which it is sold or intended for sale (the 'Applicable Jurisdiction'), any cannabis-based product, compound or medicine which under the laws of the Applicable Jurisdiction would be regulated and subject to approval and restrictions in the same manner and degree and for specific indications as an approved or registered pharmaceutical product (“Pharmaceutical-Level Regulation”), whether or not prescribed or used for that specific indication, and whether used or sold pursuant to a prescription or over the counter; provided, however, that for purposes of this Agreement (a) the following shall not be considered a “Pharmaceutical Product” (i) cannabis plants (including flowers) in their natural form; (ii) food supplements containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; (iii) cosmetic products containing cannabis as part of their ingredients, unless they are subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation; and (iv) cannabis-based toothpastes, (b) cannabis-based extracts, oils and mixtures shall not be considered a “Pharmaceutical Product”, unless and to the extent such extracts, oils or mixtures are or were subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation or have potency levels equal to or higher than an identical or substantially similar product which is subject in the Applicable Jurisdiction to Pharmaceutical-Level Regulation, and (c) notwithstanding the foregoing, in the event that identical or substantially similar cannabis-based products can be sold in any Applicable Jurisdiction as both a pharmaceutical product which is subject to Pharmaceutical-Level Regulation and as a medical or adult use cannabis product which is not subject to Pharmaceutical-Level Regulation, for purposes of this Agreement, the form of such cannabis-based product which is permitted to be sold without being subject to Pharmaceutical-Level Regulation shall not be considered a “Pharmaceutical Product”. '
Field of Use
Licensee is an early stage biopharmaceutical company engaged in the business of discovering, developing and commercializing drugs containing cannabinoids, which are based on a proprietary cannabinoid-based product platform, for the treatment of various diseases, disorders and medical conditions.

IPSCIO Record ID: 288718

License Grant
The Company entered into an agreement with an undisclosed Licensor for the exclusive manufacturing and distribution in seven eastern U.S. states of the Binske® portfolio of products.
License Property
Binske® portfolio of products is a brand known for utilizing best-in-class proprietary strains and craft ingredients in its edibles, concentrates, vaporizers, and topicals.

The Binske® line of cannabis products are made from premium artisan ingredients, and the clinically tested medicinal cannabis strains.

Field of Use
This agreement pertains to the cannabis industry.

IPSCIO Record ID: 29905

License Grant
The Licensor and Licensee amended their Agreement and expanded the scope of their partnership.The amended Agreement calls for the Licensor to serve as the developer of a new facility to be called the Illinois Medical Cannabis Center. The Licensee plans to use the IMCC to cultivate,process and distribute medical cannabis to many of the state's 52 newly Licensed medical dispensaries.  
Licensor will receive royalties and consulting fees.
License Property
When fully constructed,the IMCC will contain approximately 285,000 square feet capable of producing an estimated 50,000 pounds annually of medical cannabis owned by the Licensor. Licensor will provide working capital funding and horticultural assistance to the Licensor.
Field of Use
Medical cannabis distribution.

IPSCIO Record ID: 266631

License Grant
Licensor hereby grants to Licensee an exclusive, world-wide, License to use the HDI Technology solely in the Cannabis Application, for the purpose of processing Cannabis Materials using the SPR in the Cannabis Industry. (The aforesaid license grant is herein sometimes referred to as the “License”).

Licensor grants an exclusive license to all Licensors Intellectual Property and patented technology and creates a partnership to bring their patented controlled cavitation process to the cannabis industry.

License Property
Licensor has the Shockwave Powerâ„¢ Reactor (SPR) rights for mixing and Heating, Hydrogenating Substances, Continuous Hydrodynamics cavitation crystallization, and four other patents.

Licensor is the owner of certain Technology called ShockWave Power™. Licensor owns Intellectual Property (“IP”, defined below), manifested in Patents, Trade Secrets, and Know How, which are embodied in Licensor's proprietary ShockWave Power Reactor/Extractor (“SPR™), and which IP is useful in a variety of industries including but not limited to those industries that extract, mix, heat, hydrate, homogenize and crystallize materials.

“Cannabis Industry” means the industry where cannabis oils and other compounds containing cannabis (“Cannabis Materials”, defined below) are derived from the cannabis sativa, cannabis indica, and cannabis ruderalis plants, including marijuana and hemp, either singularly or by mixing with substances other than cannabis oils.

“Cannabis Application” means the use of the Licensor Technology to achieve a specific result when processing only “Cannabis Materials”.

“ShockWave Power Reactor/Xtractor (SPR™”) means HDI’s proprietary device that embodies the HDI Technology in performing multiple heating, mixing and extraction functions.

“ShockWave Power Reactor/Xtractor (SPR™”) means HDI’s proprietary device that embodies the HDI Technology in performing multiple heating, mixing and extraction functions.

“Standalone SPR” means an SPR mounted on a skid containing no other equipment other than that necessary to run the SPR.

Field of Use
Illustrative, but not all, areas of use of the Licensed Technology covered by this Agreement are
(i) UV light for decarboxylation of THC
(ii) Crystallization of CBD or THC
(iii) mixing of cannabis oil with other substances to create foods, beverages, or other products which are themselves not cannabis oils
(iv) Use of Electrochemistry or UltraViolate (UV) SPR’s or other advanced oxidation materials to produce radicals for the production of CBN
(v) Hydrogenation of cannabis oils
(vi) processing of hemp oils for biofuels.
(vii) Development of an SPR for supercritical CO2

IPSCIO Record ID: 28300

License Grant
The Licensee entered into a perpetual license agreement with the Licensor to make use of the Licensor's intellectual property for the cultivation of cannabis and extraction of oils and other strains of cannabis.
License Property
Licensor has developed certain proprietary know-how and other intellectual property for the cultivation of cannabis and the extraction of oils and other constituents from cannabis (the 'Intellectual Property').
Field of Use
The Licensee will use the technology for cannaibis operations within the state of Nevada.

IPSCIO Record ID: 29521

License Grant
The Licensor entered into an Agreement to License certain proprietary equipment to the Licensee, that intends to market the service of isolating particular cannabis strains.
License Property
The Technology is an indoor agricultural growing Suite with a controlled-climate for indoor agricultural growing. It is designed and engineered to cultivate medical-grade cannabis plants.
Field of Use
The Licensee will isolating particular cannabis strains for the purpose of developing tissue from those strains so as to create a consistent, brandable product of the customer’s choosing from any such strain.

IPSCIO Record ID: 362604

License Grant
The Netherlands Licensor and Licensee collaborate research in respect of the Project Technology Results, Licensor Identified Targets and/or Non-Licensor Identified Targets.

Licensor hereby assigns, transfers and conveys to XXII all right, title and interest in and to the Results. Licensor shall execute and deliver to XXII such documents, instrument and other writings reasonably requested by XXII to vest all right, title and interest in the Results in XXII.

License Property
Licensor Identified Targets means Results that constitute or are based on genes, alleles and other regulatory elements that are identified by Licensor in the course of a Project (i.e. KeySeeQ output), other than publicly known regulatory elements.

Non-Licensor Identified Targets means Results that constitute or are based on genes, alleles and other regulators that are publicly known regulatory elements.

Project Technology Results means (i) any and all protocols, methods, procedures, know-how, software, inventions, technologies and/or combinations thereof, whether in electronic form or not and whether or not laid down in protocols that (A) is developed, created and/or generated by Licensor from the execution of a Project, (B) is applicable to the Field, and (C) is expressly a deliverable of a Project as further detailed in a PAS and/or is otherwise expressly agreed by the Parties prior to the commencement of a respective Project as being a Project Technology Result, unless otherwise agreed to in writing by the Parties after the commencement of a Project and (ii) any other protocols, methods, procedures or technologies that may be separately approved by the Steering Committee as Project Technology Results.

Licensor is a global leader in plant research involving high-value genetic traits and increased crop yields.

The focus of the collaboration will include
(i) Creating a cutting-edge genetic database which utilizes the results of genomic analyses of several hundred existing, exceptional hemp/cannabis plant lines for use in the acceleration of the Company’s development and licensing of uniquely characterized and improved hemp/cannabis plants;

(ii) Enhancing genetic variation to empower Licensee’s development of new and significantly improved varieties of hemp/cannabis plant lines and varieties with highly desirable cannabinoid profiles optimized for medicinal or therapeutic applications;

(iii) Creating a proprietary and industry-leading high-resolution “molecular genetic map” of the entire cannabis plant genome to facilitate rapid, cost-effective breeding of innovative varieties of hemp/cannabis plants with distinctive agronomic traits;

(iv) Analyzing the genomic sequences of multiple species of the hemp/cannabis plant and identifying shared genetic markers, allowing Licensee to develop improved commercial hemp/cannabis plant lines more rapidly than through conventional plant breeding approaches; and

(v) Initiating the rapid-cycle generation of hemp/cannabis plant lines with distinctive cannabinoid and terpene profiles to create elite lines.

Field of Use
Field means any and all use of, research regarding, and/or commercialization of hemp and/or cannabis (all versions and types of the genus Cannabis Sativa L plant), and/or any parts thereof, for any and all purposes, including but not limited to human, medical, agricultural, veterinary, therapeutic and other such purposes.

Licensor provides Licensee access to a unique suite of crop innovation platforms, including genomics, molecular genetics, trait discovery and breeding technologies.

IPSCIO Record ID: 235008

License Grant
Licensor hereby grants Licensee, including Licensees Affiliates,

(a) during the Term, a royalty-bearing, Territory-wide license in the Licensed Field under the Patent Rights to the Licensed Technology, as well as under the Licensed Patents, the Licensed Know-how, and the Licensed Technology, regardless of whether such Licensed Patents are actually granted, to use the Licensed Know-how and Licensed Technology and to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported, any and all inventions claimed in the Licensed Patents related to the Licensed Products and/or any compounds, chemicals, substrates, devices, tools, dies, molds or any other materials whatsoever that are useful in the development and/or manufacturing and/or sale of the Licensed Products, and particularly including, without limitation, such license to develop and have developed, make and have made, use and have used, sell and have sold, offer for sale and have offered for sale, import and have imported, export and have exported Licensed Products, which license shall be exclusive even as to Licensor, and

(b) the right to grant bona fide sublicenses to third parties, to develop and have developed, to make and have made, use and have used, sell and have sold, import and have imported, export and have exported, Licensed Products, and to exercise all other rights under the License; provided, however, Licensee shall not have the right to grant any sublicense or to transfer any of its rights under the License unless each such sublicense or other transfer granted by Licensee contains terms and conditions under which the Sublicensee or transferee will be bound in the same manner as Licensee is under this Agreement. A copy of the proposed agreement shall be provided to Licensor prior to the execution of the Agreement.

License Property
Lcensed Products shall mean any and all products comprising tablets with Cannabinoids) utilizing the Licensed Technology for the delivery of a recreational, Medicinal or Pharmaceutical Cannabinoids product in specific dosage forms.

Cannabinoids means any of the chemical compounds that are the active components of the Cannabis genus of plants and its three species, Cannabis sativa, Cannabis indica, and Cannabis ruderalis; whether the compounds are synthetically produced or plant-derived, as well as cannabinoid compounds, formulations or products, that include single and/or multiple Cannabinoids including both synthetic and plant-derived Cannabinoids, as well as any and all Cannabinoid analogues. For formulations or compounds which may include combinations of API’s, other than Cannabinoids or terpenes, it is being agreed that if the API is another FDA approved Pharmaceutical, Licensor approval will be required to ensure that the API is not the subject of a current Licensor product, or the product of another licensee of the Licensor.

Medicinal shall mean any product containing marijuana, hemp or cannabis produced and sold for health, wellness, or nutritional purposes, including as herbal medicine, including products produced or sold through U.S. state-licensed or regulated marijuana programs and comparable programs in other countries and jurisdictions.

Licensed Technology shall mean the aggregate of the Licensed Inventions, the Licensed Know-how, the Licensed Products and the Licensed Patents and any other information and/or technology related to the Licensed Products and/or the design and/or the manufacturing of the Licensed Products

Licensed Patents shall mean any and all rights arising out of or resulting from (i) the patents and patent application set forth in Schedule 1.14 attached to this Agreement, as well as any additional patents or patent applications related to any aspect of any Licensed Technology Improvements, Licensed Know-how, Licensed Products, and/or Licensed Technology (as herein defined) filed prior to or during the term of this Agreement and (ii) any patent granted in respect of all such applications, as well as, without limitation, any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, re-examinations, extensions, supplementary protection certificates, confirmations, registrations, revalidations and the like, of any and all such patents and patent applications and any international equivalents thereof.

Field of Use
Licensed Field shall mean the use of Cannabinoids, together with the Licensed Technology for recreational, Medicinal and Pharmaceutical purposes in humans and animals.

IPSCIO Record ID: 30002

License Grant
The Licensor and the Licensee wish to amend the License Agreement and terms to include terms, investments, assets, revenue sharing, and ownership interest of the parties for their mutual benefit under this Agreement;

The Licensor shall have the sole ownership, rights and interest in all assets, property and facilities, or products for all mutual business, new business ventures, and opportunities under the License Agreement.

The Licensee shall pay Licensing Fees & Royalties to the Licensor, after deducting and paying all operating costs, taxes, administration, professional and other fees, or other costs of business, received under the License Agreement for the marketing, manufacturing, production, sale or distribution of the Products.

License Property
Assets include but not limited to

Land, Grows and harvested crops, CA production, Extract machinery and business operations, Once Co2 Extract machine, Buildings, Tools and equipment, Inventories Cannabis or hemp, Extracts, Packaged Goods,

Plant and plant by-products 16 strains.

Field of Use
Future endeavors Non-profit medical marijuana collectives (dispensaries),

Collective to be developed (location to be later define) and run under the Cannabis Science Brand or as specified by Cannabis Science, Other for-profit business opportunities, Treatment Centers, Drug Development Programs, Media, Retail Seed Business, Laboratories and equipment.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.